Skip to main navigation Skip to search Skip to main content

Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2

  • N. Orr
  • , Frank Dudbridge
  • , N. Dryden
  • , S. Maguire
  • , D. Novo
  • , E. Perrakis
  • , N. Johnson
  • , Maya Ghoussaini
  • , J. L. Hopper
  • , M. C. Southey
  • , Carmel Apicella
  • , J. Stone
  • , M. K. Schmidt
  • , Annegien Broeks
  • , L. J. Van'T Veer
  • , F. B. Hogervorst
  • , P. A. Fasching
  • , Lothar Haeberle
  • , A. B. Ekici
  • , M. W. Beckmann
  • L. Gibson, Zoe Aitken, Helen Warren, E. Sawyer, I. Tomlinson, Nicola Miller, Barbara Burwinkel, F. Marme, Andreas Schneeweiss, Christof Sohn, P. Guenel, T. Truong, Emilie Cordina-Duverger, M. Sanchez, S. E. Bojesen, B. G. Nordestgaard, S. F. Nielsen, Henrik Flyger, Javier Benitez, M. P. Zamora, J. I. Arias Perez, P. Menendez, Hoda Anton-Culver, S. L. Neuhausen, Hermann Brenner, A. K. Dieffenbach, Volker Arndt, Christa Stegmaier, Ute Hamann, Hiltrud Brauch, Christina Justenhoven, Thomas Bruning, Y.-D. Ko, Heli Nevanlinna, K. Aittomaki, Carl Blomqvist, S. Khan, N. Bogdanova, T. Dork, Annika Lindblom, Sara Margolin, Arto Mannermaa, Vesa Kataja, V.-M. Kosma, J. M. Hartikainen, Georgia Chenevix-Trench, Jonathan Beesley, D. Lambrechts, Matthieu Moisse, Giuseppe Floris, Benoit Beuselinck, Jenny Chang-Claude, Anja Rudolph, Petra Seibold, Dieter Flesch-Janys, Paolo Radice, Paolo Peterlongo, Bernard Peissel, V. Pensotti, F. J. Couch, J. E. Olson, Seth Slettedahl, C. Vachon, G. G. Giles, R. L. Milne, C. McLean, C. A. Haiman, B. E. Henderson, F. Schumacher, Loic Le Marchand, Jacques Simard, M. S. Goldberg, F. Labreche, Martine Dumont, V. Kristensen, G. G. Alnaes, S. Nord, A.-L. Borresen-Dale, W. Zheng, S. Deming-Halverson, M. Shrubsole, Jirong Long, Robert Winqvist, Katri Pylkas, Arja Jukkola-Vuorinen, Mervi Grip, I. L. Andrulis, J. A. Knight, Gord Glendon, Sandrine Tchatchou, Peter Devilee, Robert A. E. M. Tollenaar, C. M. Seynaeve, C. J. Van Asperen, Montserrat Garcia-Closas, J. Figueroa, S. J. Chanock, Jolanta Lissowska, Kamila Czene, H. Darabi, Mikael Eriksson, Daniel Klevebring, M. J. Hooning, Antoinette Hollestelle, C. H. M. Van Deurzen, Mieke Kriege, Per Hall, J. Li, J. Liu, Keith Humphreys, A. Cox, S. S. Cross, M. W. R. Reed, P. D. P. Pharoah, A. M. Dunning, Mitul Shah, B. J. Perkins, A. Jakubowska, Jan Lubinski, Katarzyna Jaworska-Bieniek, K. Durda, Alan Ashworth, A. Swerdlow, M. Jones, M. J. Schoemaker, Alfons Meindl, R. K. Schmutzler, Curtis Olswold, Susan Slager, A. E. Toland, Drakoulis Yannoukakos, K. Muir, Artitaya Lophatananon, S. Stewart-Brown, Pornthep Siriwanarangsan, Keitaro Matsuo, H. Ito, Hiroji Iwata, Junko Ishiguro, A. H. Wu, Chiu-Chen Tseng, David Van Den Berg, D. O. Stram, S. H. Teo, C. H. Yip, P. Kang, M. K. Ikram, X.-O. Shu, Wei Lu, Y.-T. Gao, H. Cai, Daehee Kang, J.-Y. Choi, S. K. Park, D.-Y. Noh, M. Hartman, Hui Miao, W. Y. Lim, S. C. Lee, Suleeporn Sangrajrang, Valerie Gaborieau, Paul Brennan, James McKay, P.-E. Wu, M.-F. Hou, J.-C. Yu, C.-Y. Shen, W. Blot, Qiuyin Cai, L. B. Signorello, Craig Luccarini, C. Bayes, S. Ahmed, M. Maranian, C. S. Healey, A. Gonzalez-Neira, Guillermo Pita, M. R. Alonso, N. Alvarez, Daniel Herrero, D. C. Tessier, Daniel Vincent, F. Bacot, D. J. Hunter, Sara Lindstrom, J. Dennis, Kyriaki Michailidou, M. K. Bolla, D. F. Easton, Isabel Dos Santos Silva, Olivia Fletcher, Julian Peto
  • The Breakthrough Breast Cancer Research Centre
  • Divisions of Molecular Pathology and Cancer Therapeutics
  • London School of Hygiene and Tropical Medicine
  • University of Cambridge
  • Melbourne School of Population and Global Health
  • University of Melbourne
  • The University of Western Australia
  • Antoni Van Leeuwenhoek Hospital
  • University Hospital Erlangen
  • McGill University
  • Barts and The London School of Medicine and Dentistry
  • Queen Mary University of London
  • Guy's Hospital
  • Wellcome Trust Centre for Human Genetics
  • Galway University Hospital
  • Heidelberg University
  • German Cancer Research Center
  • National Institutes of Health (NIH)
  • Université Paris-Sud
  • Gentofte University Hospital
  • Cell Division and Cancer Group
  • CIBERER Spanish Network for Rare Diseases
  • La Paz University Hospital
  • Hospital Monte Naranco
  • University of California, Irvine
  • City of Hope National Med Center
  • Saarland Cancer Registry
  • Dr. Margarete Fischer-Bosch Institute of Clinical Pharmacology
  • University of Tübingen
  • Ruhr-Universität Bochum
  • Johanniter Krankenhaus
  • University of Helsinki
  • Hannover Medical School
  • Karolinska Institutet
  • University of Eastern Finland
  • Kuopio University Hospital
  • Jyväskylä Central Hospital
  • QIMR Berghofer Medical Research Institute
  • Vesalius Research Center (VRC)
  • University of Leuven
  • KU Leuven– University Hospital Leuven
  • University Medical Center Hamburg-Eppendorf
  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
  • IFOM - The FIRC Institute of Molecular Oncology
  • Cogentech Cancer Genetic Test Laboratory
  • Mayo Clinic
  • Cancer Council Victoria
  • Alfred Hospital
  • Keck School of Medicine of USC
  • The University of Hawaii Cancer Center
  • Faculty of Pharmacy
  • McGill University
  • McGill University Health Centre, Royal Victoria Hospital
  • Université de Montréal
  • Faculty of Medicine
  • University of Oslo
  • Vanderbilt-Ingram Cancer Center
  • University of Oulu
  • University Hospital of Oulu
  • University of Toronto/Lunenfeld-Tanenbaum Research Institute
  • University of Toronto Faculty of Medicine
  • University of Toronto
  • Leiden University Medical Center
  • Erasmus MC Cancer Institute
  • National Cancer Institute (NCI)
  • M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology
  • Erasmus MC
  • A*STAR
  • University of Sheffield
  • University of Sussex
  • Pomeranian Medical University in Szczecin
  • Technical University Munich
  • University of Cologne
  • Ohio State University
  • Institute of Biosciences and Applications
  • Warwick Medical School
  • University of Manchester
  • Ministry of Public Health
  • Kyushu University
  • Aichi Cancer Center Research Institute
  • Sime Darby Medical Centre
  • University Malaya Cancer Research Institute
  • National University of Singapore
  • Shanghai Center for Disease Control and Prevention
  • Shanghai Cancer Institute
  • Seoul National University College of Medicine
  • Seoul National University
  • National University of Singapore
  • National University Health System
  • Cancer Science Institute of Singapore
  • National Cancer Institute of Thailand
  • Intl. Agency for Research on Cancer
  • Academia Sinica Taiwan
  • Academia Sinica, Institute of Biomedical Sciences
  • Kaohsiung Medical University Hospital
  • Tri-Service General Hospital
  • China Medical University
  • International Epidemiology Institute
  • Dana-Farber Harvard Cancer Center
  • Harvard School of Public Health

Research output: Contribution to a Journal (Peer & Non Peer)Articlepeer-review

37 Citations (Scopus)

Abstract

We recently identified a novel susceptibility variant, rs865686, for estrogen-receptor positive breast cancer at 9q31.2. Here, we report a fine-mapping analysis of the 9q31.2 susceptibility locus using 43 160 cases and 42 600 controls of European ancestry ascertained from 52 studies and a further 5795 cases and 6624 controls of Asian ancestry from nine studies. Single nucleotide polymorphism (SNP) rs676256 was most strongly associated with risk in Europeans (odds ratios [OR] = 0.90 [0.88-0.92]; P-value = 1.58 x 10(-25)). This SNP is one of a cluster of highly correlated variants, including rs865686, that spans 14.5 kb. We identified two additional independent association signals demarcated by SNPs rs10816625 (OR = 1.12 [1.08-1.17]; P-value = 7.89 x 10(-09)) and rs13294895 (OR = 1.09 [1.06-1.12]; P-value = 2.97 x 10(-11)). SNP rs10816625, but not rs13294895, was also associated with risk of breast cancer in Asian individuals (OR = 1.12 [1.06-1.18]; P-value = 2.77 x 10(-05)). Functional genomic annotation using data derived from breast cancer cell-line models indicates that these SNPs localise to putative enhancer elements that bind known drivers of hormone-dependent breast cancer, including ER-alpha, FOXA1 and GATA-3. In vitro analyses indicate that rs10816625 and rs13294895 have allele-specific effects on enhancer activity and suggest chromatin interactions with the KLF4 gene locus. These results demonstrate the power of dense genotyping in large studies to identify independent susceptibility variants. Analysis of associations using subjects with different ancestry, combined with bioinformatic and genomic characterisation, can provide strong evidence for the likely causative alleles and their functional basis.
Original languageEnglish (Ireland)
Pages (from-to)2966-2984
Number of pages19
JournalHuman Molecular Genetics
Volume24
Issue number10
DOIs
Publication statusPublished - 1 May 2015

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2'. Together they form a unique fingerprint.

Cite this